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For almost two decades, studies have shown collectins
to be critical for effective antimicrobial defense of the
airways. Members of this protein family, which includes
surfactant proteins (SP)-A and D, provide broad-spectrum
protection through promoting the aggregation and
clearance of pathogens. Interestingly, these proteins may
also modulate the immune response, and growing
evidence has shown collectins to be protective against
several markers of inflammation and injury. In a recent
study by Herrera-Ramos and colleagues, genetic variants
of collectins were examined in Spanish patients with the
pandemic 2009 H1N1 influenza A virus. Comparing
genotypes for measures of poor lung function,
inflammation, and admission to intensive care, these
authors identified three variants of the SP-A gene SFTPA2
that positively correlated with flu severity. Remarkably,
they also found the haplotype 1A1 of SFTPA2 to be
protective against these indicators, suggesting that
targeted therapy with a recombinant form of SP-A2 may
improve patient outcome. Although further work is
required to confirm the specificity and efficacy of SP-A in
therapeutic H1N1 protection, this study is one of the first
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Antigenic diversity among circulating influenza A virus
(IAV) strains poses a challenge for the adaptive immune
system in the rapid control of infection, especially without
prior vaccination. However, the innate immune system is
equipped to control early stages of viral replication with a
repertoire of broad-spectrum, pathogen-recognition mole-
cules called collectins.
In the previous issue of Critical Care, Herrera-Ramos
and colleagues [1] examined a panel of collectin genes -
mannose-binding lectin (MBL2), surfactant proteins A1
and A2 (SFTPA1/SFTPA2), and surfactant protein D
(SFTPD) - in Spanish patients with pandemic 2009 H1N1
infection. The objective of their study was to identify gen-
etic variants that predisposed patients to severe influenza.
The authors defined infection severity by a number of indi-
cators, including poor lung function (requirement for
mechanical ventilation, acute respiratory distress syndrome,
or acute respiratory failure), hypoxemia (ratio of partial
pressure of oxygen in arterial blood to the fraction of in-
spired oxygen, or PaO2/FiO2), inflammation (bacteremia or
secondary pneumonia), and patient instability (need for in-
tensive care). They identified three polymorphisms (alleles
rs1965708-C, rs1059046-A, and the haplotype 1A0) that
significantly correlated with poor clinical outcome, all of
The indication that SFTPA2 variants have the greatest
effect on IAV control aligns well with previous work on
collectin-virus interactions. A majority of the IAV sur-
face is composed of the protein hemagglutinin, which
can be modified by glycosylation and made susceptible
to collectin binding. However, while surfactant protein
(SP)-D and MBL recognize highly glycosylated virions,
they have poor efficacy against strains with minor glyco-
sylation, such as pandemic H1N1 [2,3]. In contrast, SP-
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glutinin. Therefore, SP-A efficiently neutralizes even the
poorly glycosylated strains of influenza [4,5]. Finally,
SFTPA2 expression has been found in both the upper and
lower airways, making it a good candidate for H1N1 inhib-
ition in both regions [6, 7].
Overall, the data set presented provides good clinical sup-
port for the role of SFTPA2 in the control of pandemic
H1N1, although the mechanism by which SP-A may act
is still ambiguous. In theory, SP-A could improve patient
outcome through direct viral neutralization or indirectly
through maintaining lung homeostasis and constraining
the collateral effects of inflammation [8]. Additional mea-
sures of viral replication in patient airways may help to clar-
ify whether SP-A is acting in a truly anti-viral or anti-
inflammatory manner.
Perhaps it is worth mentioning that the study provided
no information about the status of the protein product
between patients. In addition to sequence variation, dif-
ferences in the quantity of SP-A and other collectins
may influence clinical outcome [9]. Indeed, other groups
have started to uncover subtleties between SFTPA alleles
and protein translation efficiency in vitro [10, 11]. Post-
translational regulation and cleavage of SP-A in inflamed
lungs may also abrogate the ability of collectin to bind
targets [12]. It is possible that some of the genetic vari-
ants identified by the current group are subject to dif-
ferent rates of protein turnover in the lungs, with
downstream effects on flu severity. However, this rather
complex question will require further protein-based
examination of patient airways.
Nevertheless, the work presented by Herrera-Ramos
and colleagues has identified promising targets for inves-
tigation. The variants rs1965708-C (changes amino acid
223 in the globular domain; Q223K) and rs1059046-A
(changes amino acid 9 in the signal peptide; T9N) and
the haplotype 1A0 (differs from A1 at both amino acids 9
and 223) may have prognostic value for severe flu, al-
though it is appropriate to note that this study included
only patients of Spanish descent. Testing the predictive
power of these variants in a broader cohort will be ne-
cessary before adopting them as clinical markers.
Finally, the authors identified the SFTPA2 haplotype
1A1 to be protective for a number of indicators (acute
respiratory failure, acute respiratory distress syndrome,
PaO2/FiO2 ratio, and mechanical ventilation), suggesting
that this variant may be examined for future therapy
against pandemic H1N1. Although the idea of delivering
a single recombinant protein to improve flu severity may
appeal to many of us, we must be mindful that IAV has
incredible potential to acquire genetic mutations ran-
domly and under intense selective pressure. Neverthe-
less, since SP-A is posited to bind IAV through a
conserved sialic acid-hemagglutinin interaction, it mayhave clinical value. Most importantly, if SP-A can also
aggressively regulate the host response irrespective of
pathogen specificity we may have a potential therapy on
our hands.
Conclusions
Herrera-Ramos and colleagues have demonstrated the
value of tailoring treatment for both the patient geno-
type and influenza strain in exceptional cases of H1N1
infection. They have identified three genetic variants of
SFTPA2 that associate with flu severity (rs1965708-C,
rs1059046-A, and haplotype 1A0) and one with protec-
tion (1A1). Continuing efforts to bridge our understand-
ing of genetic variation and flu progression will be a
valuable direction for future clinical care.
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